This research aims to evaluate the safety and antitumor activity of lenvatinib combined with pembrolizumab in patients with unresectable hepatocellular carcinoma.
Phase Ib trial design
Combination treatment of lenvatinib and pembrolizumab
Focus on safety and antitumor activity
Combination therapy displayed promising antitumor activity in patients with uHCC
Toxicities observed were manageable and no unexpected safety signals were reported
Abstract
Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC. Toxicities were manageable, with no unexpected safety signals.